A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

NCT00870194 on ClinicalTrials.gov · last registry update 2015-04-09

An unusually large phase 4: 255 participants, more than double the 75 typical for the stage. The sponsor logged completion for April 2010. Primary outcome, as filed: Change in HbA1c (Percent). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 255
Started: 2009-03
Primary completion: 2010-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c (Percent)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.